Orioles reliever Keegan Akin to miss 2024 season after Tommy John surgery

Boston – The Baltimore Orioles confirmed on Tuesday that right‑handed reliever Keegan Akin will undergo Tommy John surgery, effectively ending his 2024 season. The move follows an MRI that revealed a torn ulnar collateral ligament (UCL) in his throwing elbow, a diagnosis that forces the 29‑year‑old to begin a year‑plus rehabilitation process.

Core developments

The club’s official statement, echoed by MLB.com, said Akin will have the procedure performed by Dr. James Andrews’ team in Florida. The surgery, known formally as UCL reconstruction, replaces the damaged ligament with a tendon graft and typically requires 12 to 18 months of structured rehab before a pitcher can return to major‑league action.

According to the Orioles’ medical staff, the injury was identified after Akin experienced lingering soreness in his elbow during a routine bullpen session in early June. Subsequent imaging confirmed a complete tear, prompting the decision for surgery rather than a non‑operative route. The organization noted that Akin’s health and long‑term effectiveness were the primary considerations.

Statistically, Akin entered the 2024 season as a key middle‑relief option. While the exact numbers vary across reports, each source highlighted his reliability out of the pen last year, where he posted a sub‑3.00 ERA across more than 50 appearances and struck out a comparable number of batters to innings pitched. His 2024 performance, though limited, showed a solid strikeout rate and a low walk percentage before the elbow issue surfaced.

Team officials, including manager Brandon Hyde, emphasized Akin’s professionalism and the positive outlook for his recovery. Hyde told reporters, "Keegan’s work ethic is second‑to‑none, and we’ll support him every step of the way," a sentiment echoed in the MLB Trade Rumors release. General manager Mike Elias also indicated that the club will explore internal options and potential free‑agent signings to fill the bullpen gap left by Akin’s absence.

Why it matters

Tommy John surgery has become a relatively common, albeit serious, procedure for pitchers. For a team like Baltimore, which is in the midst of a competitive window, losing a dependable arm can ripple through the roster. Akin’s ability to bridge the gap between the starter and the late‑inning specialists has been a cornerstone of the Orioles’ bullpen strategy, allowing the staff to preserve high‑leverage relievers for close games.

The Orioles have already shuffled roles this season, promoting younger arms and leveraging veterans to maintain depth. Akin’s absence forces the club to accelerate those plans, potentially giving more opportunities to emerging pitchers such as Joe (name omitted per source constraints) or to seek a veteran presence on the market. Moreover, the timing of the surgery aligns with the offseason, meaning the team can assess Akin’s progress before the 2025 spring training and make informed decisions about roster construction.

From a broader perspective, Akin’s case adds to the growing dataset of pitchers undergoing UCL reconstruction. While many return to previous performance levels, a subset experiences declines in velocity or command. The Orioles’ medical team, known for integrating advanced biomechanics, will likely tailor Akin’s rehab to mitigate those risks, a point highlighted by the MASN article, which noted the club’s commitment to a “gradual, data‑driven” approach.

Differing viewpoints and reactions

Analysts at CBS Sports and RotoWire weighed in on the long‑term implications. CBS Sports suggested that Akin’s age and track record give him a favorable prognosis, noting that pitchers who undergo the surgery after age 28 often return to form if the rehab is disciplined. In contrast, RotoWire cautioned that the Orioles’ bullpen depth could be tested if Akin’s recovery extends beyond the typical 12‑month window, especially given the competitive nature of the American League East.

Fans expressed a mixture of support and concern on social media, with many praising Akin’s perseverance and others questioning how the team will address the immediate void. The Baltimore Sun captured this sentiment, quoting a longtime season ticket holder who said, "We’ve seen Keegan step up all season; it hurts to see him go, but we trust the club’s medical staff."

From the front office, Elias remained optimistic, stating that the organization’s depth chart is “flexible enough” to absorb the loss while still pursuing strategic moves at the trade deadline. Hyde added that the bullpen will continue to “lean on the guys who have been here all year,” underscoring the team’s reliance on internal development.

What’s next

Following the surgery, Akin will embark on a structured rehabilitation program that begins with limited range‑of‑motion exercises and gradually progresses to throwing sessions. The Orioles plan to monitor his progress through regular medical assessments, with an anticipated timeline that could see him back in minor‑league action by the start of the 2025 season.

In the short term, Baltimore is expected to promote a minor‑league reliever to the major‑league roster and may explore a low‑cost free‑agent signing to bolster the bullpen. The team’s front office will also evaluate trade options, though any move will have to balance immediate needs with the longer‑term financial flexibility the Orioles have cultivated.

For Akin, the focus shifts from the mound to recovery. The player’s agent, who declined to comment on contract specifics, reiterated that Akin remains “fully committed to the rehab process and eager to return to the game he loves.” As the season draws to a close, the Orioles will look to the offseason to fill the gap, while fans wait for updates on Akin’s progress, hoping the surgeon’s scalpel will bring him back stronger than before.